NCT03673956 is a Phase 1, PHASE2 clinical trial of Mupirocin in Chronic Rhinosinusitis (Diagnosis), sponsored by Mayo Clinic.

Who is sponsoring NCT03673956?

NCT03673956 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03673956?

Interventions in NCT03673956: Mupirocin, Tobramycin, Levofloxacin, Vancomycin.

What condition does NCT03673956 study?

NCT03673956 studies Chronic Rhinosinusitis (Diagnosis).

Is NCT03673956 still recruiting?

NCT03673956 is currently completed. Last updated 20 April 2022.

Are results published for NCT03673956?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-04-20 · How we verify

NCT03673956

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Antibiotics in Chronic Rhinosinusitis

Completed Phase 1, PHASE2 Results posted Last updated 20 April 2022

What this trial tests

Phase 1, PHASE2 trial testing Mupirocin in Chronic Rhinosinusitis (Diagnosis) in 19 participants. Completed in 1 February 2021.

Timeline

26 September 2018

Primary endpoint
1 February 2021

1 February 2021

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	26 September 2018
Primary completion	1 February 2021
Estimated completion	1 February 2021
Sites	1 location across United States

Drugs / interventions tested

Mupirocin (MUPIROCIN) — full drug profile →
Tobramycin (tobramycin) — full drug profile →
Levofloxacin (Levofloxacin) — full drug profile →
Vancomycin (vancomycin) — full drug profile →

Conditions studied

Chronic Rhinosinusitis (Diagnosis) — all drugs for Chronic Rhinosinusitis (Diagnosis) →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 80, any sex, with Chronic Rhinosinusitis (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Subjects Who Developed Antibiotic Resistance Organisms Primary · Post-intervention (within 21 days of intervention completion)

Number of subjects who developed new antibiotic resistance organisms measured by nasal swab of the affected sinonasal cavity and sent for stain, culture, and sensitivity.

Group	Value	95% CI
Mupirocin Antibiotic Nasal Saline Rinse	0
Tobramycin Topical Antibiotic Nasal Saline Rinse	0
Levofloxacin Topical Antibiotic Nasal Saline Rinse	1
Vancomycin Topical Antibiotic Nasal Saline Rinse	0

Change in Patient Symptoms as Measured by the Sino-Nasal Outcomes Test (SNOT-22) Survey Secondary · Baseline, Post-intervention (within 21 days of intervention completion)

Scores are measured from 0-5 in a 22-item validated survey. Total scores range from 0-110 with higher scores indicating greater burden of sinonasal symptoms.

Group	Value	95% CI
Mupirocin Antibiotic Nasal Saline Rinse	-18	± 21.8
Tobramycin Topical Antibiotic Nasal Saline Rinse	14
Levofloxacin Topical Antibiotic Nasal Saline Rinse	-25.5	± 34.6
Vancomycin Topical Antibiotic Nasal Saline Rinse	-11

Change in Patient Physical Exam as Measured by the Lund-Kennedy Endoscopic Exam Scores. Secondary · Baseline, Post-intervention (within 21 days of intervention completion)

Scores are measured on a 0-2 scale for nasal polyps, edema, and secretions in both right and left nasal cavities. Total scores range from 0 to 12 with higher scores indicating greater evidence of sinonasal disease on physical exam.

Group	Value	95% CI
Mupirocin Antibiotic Nasal Saline Rinse	-5.3	± 2.8
Tobramycin Topical Antibiotic Nasal Saline Rinse	-3
Levofloxacin Topical Antibiotic Nasal Saline Rinse	-2.4	± 2.4
Vancomycin Topical Antibiotic Nasal Saline Rinse	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected from baseline to end of study for a total of approximately 2 months on all participants.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Mupirocin Antibiotic Nasal Saline Rinse

Serious: 0/12 (0%)

Deaths: 0/12

Tobramycin Topical Antibiotic Nasal Saline Rinse

Serious: 0/1 (0%)

Deaths: 0/1

Levofloxacin Topical Antibiotic Nasal Saline Rinse

Serious: 0/5 (0%)

Deaths: 0/5

Vancomycin Topical Antibiotic Nasal Saline Rinse

Serious: 0/1 (0%)

Deaths: 0/1

Other adverse events (5 terms — click to expand)

Reaction	System	Mupirocin Antibiotic Nasal…	Tobramycin Topical Antibio…	Levofloxacin Topical Antib…	Vancomycin Topical Antibio…
Headache	Nervous system disorders	—	—	—	—
Face Pain	General disorders	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Facial Pressure	General disorders	—	—	—	—
Nasal Drainage	General disorders	—	—	—	—

Data from ClinicalTrials.gov NCT03673956 adverse events section.

Sponsor's own description

Researchers are trying to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Mupirocin

Trials testing the same drug.

NCT05251584 — Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related Infection · NA · unknown
NCT03489629 — STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) · Phase 2 · completed
NCT03173053 — S. Aureus Decolonization in HPN Patients. · NA · terminated
NCT02216227 — Checklist to Prevent MRSA Surgical Site Infections · NA · completed
NCT01269541 — MESS-study MRSA Eradication Study Skåne · NA · completed

Other recruiting trials for Chronic Rhinosinusitis (Diagnosis)

Currently open trials in the same condition.

NCT05427695 — Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis · Phase 2 · recruiting
NCT06986629 — Effect of Photobiostimulation Versus Pulsed Electromagnetic Field on Quality of Life in Adults With Chronic Rhinosinusit · NA · recruiting
NCT05882903 — The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis · Phase 2 · recruiting
NCT05857228 — Viral and Epigenetic Influences in CRSwNP · active not recruiting
NCT04670172 — Real-Life Chronic Rhinosinusitis Outcome Registry · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03673956 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 20 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03673956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing